ProPhase Labs Company Top Insiders
| PRPH Stock | USD 5.06 0.10 1.94% |
ProPhase Labs employs about 113 people. The company is managed by 15 executives with a total tenure of roughly 89 years, averaging almost 5.0 years of service per executive, having 7.53 employees per reported executive. Assessment of ProPhase Labs' management performance can provide insight into the firm performance.
| Ted Karkus Chairman Chairman and CEO |
ProPhase |
ProPhase Labs' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with ProPhase Labs' future performance. Based on our forecasts, it is anticipated that ProPhase will maintain a workforce of under 110 employees by May 2024.ProPhase Labs Management Team Effectiveness
The company has return on total asset (ROA) of (0.1505) % which means that it has lost $0.1505 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.297) %, meaning that it created substantial loss on money invested by shareholders. ProPhase Labs' management efficiency ratios could be used to measure how well ProPhase Labs manages its routine affairs as well as how well it operates its assets and liabilities. The ProPhase Labs' current Return On Tangible Assets is estimated to increase to -0.21. The ProPhase Labs' current Return On Capital Employed is estimated to increase to -0.29. As of now, ProPhase Labs' Intangible Assets are increasing as compared to previous years. The ProPhase Labs' current Other Assets is estimated to increase to about 1.6 M, while Non Currrent Assets Other are forecasted to increase to (9.8 M).The ProPhase Labs' current Net Income Applicable To Common Shares is estimated to increase to about 7.6 M, while Common Stock Shares Outstanding is projected to decrease to under 15.2 M.
ProPhase Labs Workforce Comparison
ProPhase Labs is rated below average in number of employees category among related companies. The total workforce of Health Care industry is at this time estimated at about 99,519. ProPhase Labs adds roughly 113 in number of employees claiming only tiny portion of equities under Health Care industry.
ProPhase Labs Profit Margins
The company has Profit Margin (PM) of (0.38) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (3.24) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $3.24.| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.58 | 0.3659 |
|
|
ProPhase Labs Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific ProPhase Labs insiders, such as employees or executives, is commonly permitted as long as it does not rely on ProPhase Labs' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, ProPhase Labs insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2023-06-01 | 3.0 | 6 | 2 | 720,000 | 150,000 |
| 2023-03-01 | 0.4 | 2 | 5 | 1,100,000 | 1,737,568 |
| 2022-12-01 | 0.5 | 1 | 2 | 600,000 | 917,291 |
| 2022-09-01 | 4.0 | 4 | 1 | 720,000 | 316,605 |
| 2021-06-01 | 5.0 | 5 | 1 | 343,943 | 120,000 |
| 2020-09-01 | 4.0 | 8 | 2 | 441,205 | 104,150 |
| 2020-03-01 | 3.0 | 3 | 1 | 108,346 | 100,000 |
| 2018-06-01 | 0.5 | 2 | 4 | 250,000 | 335,321 |
| 2017-12-01 | 0.2 | 1 | 5 | 600,000 | 1,049,789 |
| 2017-09-01 | 0.4286 | 3 | 7 | 360,000 | 2,783,255 |
| 2015-06-01 | 5.0 | 5 | 1 | 610,000 | 0.00 |
| 2010-12-01 | 1.3333 | 8 | 6 | 841,604 | 10,000 |
| 2007-09-01 | 2.0 | 4 | 2 | 149,000 | 9,000 |
| 2006-12-01 | 0.5 | 3 | 6 | 150,000 | 300,000 |
| 2006-06-01 | 0.5556 | 5 | 9 | 825,000 | 1,359,875 |
| 2006-03-01 | 0.6 | 3 | 5 | 25,000 | 40,125 |
| 2005-12-01 | 7.0 | 7 | 1 | 300,000 | 10,000 |
| 2004-12-01 | 2.3333 | 7 | 3 | 215,000 | 22,487 |
| 2003-12-01 | 7.0 | 7 | 1 | 179,000 | 18,000 |
| 2003-09-01 | 0.125 | 1 | 8 | 15,000 | 34,113 |
ProPhase Labs Notable Stakeholders
A ProPhase Labs stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as ProPhase Labs often face trade-offs trying to please all of them. ProPhase Labs' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting ProPhase Labs' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Ted Karkus | Chairman and CEO | Profile | |
| Jason Karkus | President Diagnostics | Profile | |
| Robert Cuddihy | CFO, COO, Principal Accounting Officer and Executive VP | Profile | |
| Alice Lioi | EVP BioPharma | Profile | |
| Mark Burnett | Independent Director | Profile | |
| James McCubbin | Compliance Officer, Independent Director and Member of Audit Committee | Profile | |
| Mark Leventhal | Independent Director | Profile | |
| Louis Gleckel | Independent Director | Profile | |
| Jason Barr | Director | Profile | |
| Billy White | Consultant | Profile | |
| Sergio Miralles | Executive Diagnostics | Profile | |
| Robert Morse | Principal Controller | Profile | |
| Kamal Obbad | Senior Genomics | Profile | |
| Monica Brady | Principal Financial Officer & Principal Accounting Officer | Profile | |
| Jed Latkin | Chief Department | Profile |
About ProPhase Labs Management Performance
The success or failure of an entity such as ProPhase Labs often depends on how effective the management is. ProPhase Labs management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of ProPhase management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the ProPhase management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.23) | (0.21) | |
| Return On Capital Employed | (0.30) | (0.29) | |
| Return On Assets | (0.18) | (0.17) | |
| Return On Equity | (0.34) | (0.32) |
The data published in ProPhase Labs' official financial statements usually reflect ProPhase Labs' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of ProPhase Labs. For example, before you start analyzing numbers published by ProPhase accountants, it's critical to develop an understanding of what ProPhase Labs' liquidity, profitability, and earnings quality are in the context of the Pharmaceuticals space in which it operates.
Please note, the presentation of ProPhase Labs' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, ProPhase Labs' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in ProPhase Labs' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of ProPhase Labs. Please utilize our Beneish M Score to check the likelihood of ProPhase Labs' management manipulating its earnings.
ProPhase Labs Workforce Analysis
Traditionally, organizations such as ProPhase Labs use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare ProPhase Labs within its industry.ProPhase Labs Manpower Efficiency
Return on ProPhase Labs Manpower
| Revenue Per Employee | 392.8K | |
| Revenue Per Executive | 3M | |
| Net Loss Per Employee | 148.5K | |
| Net Loss Per Executive | 1.1M | |
| Working Capital Per Employee | 236.5K | |
| Working Capital Per Executive | 1.8M |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ProPhase Labs. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. For more detail on how to invest in ProPhase Stock please use our How to Invest in ProPhase Labs guide.You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Complementary Tools for ProPhase Stock analysis
When running ProPhase Labs' price analysis, check to measure ProPhase Labs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ProPhase Labs is operating at the current time. Most of ProPhase Labs' value examination focuses on studying past and present price action to predict the probability of ProPhase Labs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ProPhase Labs' price. Additionally, you may evaluate how the addition of ProPhase Labs to your portfolios can decrease your overall portfolio volatility.
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine |
Is ProPhase Labs' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ProPhase Labs. If investors know ProPhase will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ProPhase Labs listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.95) | Earnings Share (0.98) | Revenue Per Share 2.579 | Quarterly Revenue Growth (0.84) | Return On Assets (0.15) |
The market value of ProPhase Labs is measured differently than its book value, which is the value of ProPhase that is recorded on the company's balance sheet. Investors also form their own opinion of ProPhase Labs' value that differs from its market value or its book value, called intrinsic value, which is ProPhase Labs' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ProPhase Labs' market value can be influenced by many factors that don't directly affect ProPhase Labs' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ProPhase Labs' value and its price as these two are different measures arrived at by different means. Investors typically determine if ProPhase Labs is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ProPhase Labs' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.